Painless Ultrasonic Gastroscopy Examination
Conditions
Interventions
Observation group:For preemptive analgesia, low-concentration remifentanil (Yichang Humanwell Pharmaceutical Co., Ltd., NMPA Approval No. H20030197) at a dose of 0.3 µg/kg is administered intravenousl
Control group:For preemptive analgesia, low-concentration remifentanil (Yichang Humanwell Pharmaceutical Co., Ltd., NMPA Approval No. H20030197) at 0.3 µg/kg is slowly administered intravenously over
Sponsors
The First Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Undergoing painless ultrasonic gastroscopy; 2. Aged 18–64 years; 3. Body mass index (BMI) 18–30 kg/m²; 4. American Society of Anesthesiologists (ASA) physical status classification I–II; 5. Willing to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Complicated with severe respiratory system diseases or infections; 2. Complicated with a history of severe cardiovascular and cerebrovascular diseases; 3. Complicated with cognitive impairment or mental illnesses; 4. Complicated with insufficiency of organ functions such as liver and kidney; 5. With a history of alcohol abuse or drug addiction; 6. Allergic to the study drug; 7. Complicated with other contraindications to painless gastroscopy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mean arterial pressure, MAP;heart rate, HR;percutaneous arterial oxygen saturation, SpO2; | — |
Secondary
| Measure | Time frame |
|---|---|
| number of successful sedation/anesthesia cases;onset time of sedation/anesthesia;recovery time; | — |
Countries
China
Contacts
Public ContactZhuqing Rao
The First Affiliated Hospital of Nanjing Medical University
Outcome results
None listed